Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $50,000,000. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 19, 2025, subject to satisfaction of customary closing conditions.